Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:43 AM
Ignite Modification Date: 2025-12-25 @ 10:56 PM
NCT ID: NCT00919867
Description: Safety population consists of all subjects who received at least 1 dose of study drug and had at least 1 post-dose safety assessment.
Frequency Threshold: 5
Time Frame: None
Study: NCT00919867
Study Brief: A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
SPD503 Alone Single 4 mg dose of extended-release Guanfacine HCl None None 0 40 9 40 View
Vyvanse Alone Single 50 mg dose None None 0 41 6 41 View
SPD503 + Vyvanse SPD503 (single 4 mg dose) + Vyvanse (single 50 mg dose) coadministered None None 0 41 6 41 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dizziness None Nervous system disorders None View
Dizziness Postural None Nervous system disorders None View
Headache None Nervous system disorders None View